Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study

INTRODUCTION: Plasma circulating tumor DNA (ctDNA) is an ideal approach to detecting the epidermal growth factor receptor (EGFR) T790M mutation, which is a major mechanism of resistance to first-generation EGFR-tyrosine kinase inhibitor (TKI) therapy. The present study aimed to explore the associati...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shirong, Zhu, Lucheng, Xia, Bing, Chen, Enguo, Zhao, Qiong, Zhang, Xiaochen, Chen, Xueqin, Chen, Xufeng, Ma, Shenglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993134/
https://www.ncbi.nlm.nih.gov/pubmed/29789021
http://dx.doi.org/10.1186/s40880-018-0303-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993134/
https://www.ncbi.nlm.nih.gov/pubmed/29789021
http://dx.doi.org/10.1186/s40880-018-0303-2

Ejemplares similares